32 results on '"Gingrich, Diane E."'
Search Results
2. Supplementary Figure 3 from CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers
3. Supplementary Table 1, Figures 1-2 from CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers
4. A novel, one-pot preparation of N-methyl-α-amino acid dipeptides from oxazolidinones and amino acids
5. Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)
6. Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases
7. 2,7-Pyrrolo[2,1- f][1,2,4]triazines as JAK2 inhibitors: Modification of target structure to minimize reactive metabolite formation
8. A novel preparation of scalemic N-methyl-alfa-amino acids
9. A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-a]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779
10. Discovery of an Orally Efficacious Inhibitor of Anaplastic Lymphoma Kinase
11. CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers
12. Development and Scale-Up of an Optimized Route to the ALK Inhibitor CEP-28122
13. 2,7-Disubstituted-Pyrrolotriazine Kinase Inhibitors with an Unusually High Degree of Reactive Metabolite Formation
14. Depletion of Autoreactive Plasma Cells and Treatment of Lupus Nephritis in Mice Using CEP-33779, a Novel, Orally Active, Selective Inhibitor of JAK2
15. 2,7-Disubstituted-pyrrolo[2,1-f][1,2,4]triazines: New Variant of an Old Template and Application to the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors with in Vivo Antitumor Activity
16. Abstract 3574: Identification and preclinical characterization of CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase, in lymphoma and non-small cell lung cancer models
17. A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis
18. ChemInform Abstract: Antineoplastic Agents. Part 395. Isolation and Structure of Agelagalastatin from the Papua New Guinea Marine Sponge Agelas sp.
19. Advances in the development of kinase inhibitor therapeutics for Alzheimer's disease
20. Synthesis, Modeling, and In Vitro Activity of (3‘S)-epi-K-252a Analogues. Elucidating the Stereochemical Requirements of the 3‘-Sugar Alcohol on trkA Tyrosine Kinase Activity
21. A New Class of Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Structure−Activity Relationships for a Series of 9-Alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the Identification of CEP-5214 and Its Dimethylglycine Ester Prodrug Clinical Candidate CEP-7055
22. Synthesis and Kinase Inhibitory Activity of 3′‐(S)‐epi‐K‐252a.
23. Synthesis and kinase inhibitory activity of 3′-(S)-epi-K-252a
24. ChemInform Abstract: A Novel, One‐Pot Preparation of N‐Methyl‐α‐amino Acid Dipeptides from Oxazolidinones and Amino Acids.
25. A novel, one-pot preparation ofN-methyl-α-amino acid dipeptides from oxazolidinones and amino acids
26. Antineoplastic agents. Part 395.1 Isolation and structure of agelagalastatin from the Papua New Guinea marine sponge Agelas sp.
27. Inhibition of metalloproteinase by futoenone derivatives
28. A Selective, Orally Bioavailable1,2,4-Triazolo[1,5-a]pyridine-Based Inhibitor ofJanus Kinase 2 for Use inAnticancer Therapy: Discovery of CEP-33779.
29. Discovery of an OrallyEfficacious Inhibitor of Anaplastic Lymphoma Kinase.
30. Multinuclear NMR spectroscopic studies of aryltrimethylsilanes and aryldimethylphosphaneboranes
31. ChemInform Abstract: Antineoplastic Agents. Part 395. Isolation and Structure of Agelagalastatin from the Papua New Guinea Marine Sponge Agelas sp.
32. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.